Leukotrienes are not essential for the efficacy of a heterologous vaccine against Mycobacterium tuberculosis infection

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 7, 2010, Pages 645-650

  Franco, L H ^a   Oliveira e Paula, M ^a   Wowk, P F ^a   da Fonseca, D M ^a   Sergio C A ^a   Fedatto, P F ^a   Gembre, A F ^a   Ramos, S G ^b   Silva, C L ^a   Medeiros, A I ^c   Faccioli, L H ^b   Bonato, V L D ^a  

^a Departamento de Bioquímica e Imunologia   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Leukotrienes; Prime boost immunization; Tuberculosis

Indexed keywords

ACEBUTOLOL; BCG VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 65; LEUKOTRIENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; INFECTION PREVENTION; LEUKOCYTE MIGRATION; MOUSE; NONHUMAN; TUBERCULOSIS;

ANIMALIA; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 77954731194     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500053     Document Type: Article

References (20)

1. WHO. Global tuberculosis control. Geneva: World Health Organization; 2008.
2. Algood HM, Chan J, Flynn JL. Chemokines and tuberculosis. Cytokine Growth Factor Rev 2003; 14: 467-477.
3. Silva CL, Bonato VL, Lima KM, Coelho-Castelo AA, Faccioli LH, Sartori A, et al. Cytotoxic T cells and mycobacteria. FEMS Microbiol Lett 2001; 197: 11-18.
4. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-572.
5. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995; 155: 2515-2524.
6. Peres CM, de Paula L, Medeiros AI, Sorgi CA, Soares EG, Carlos D, et al. Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis. Microbes Infect 2007; 9: 483-489.
7. Medeiros AI, Sa-Nunes A, Turato WM, Secatto A, Frantz FG, Sorgi CA, et al. Leukotrienes are potent adjuvant during fungal infection: effects on memory T cells. J Immunol 2008; 181: 8544-8551.
8. Medeiros AI, Sa-Nunes A, Soares EG, Peres CM, Silva CL, Faccioli LH. Blockade of endogenous leukotrienes exacerbates pulmonary histoplasmosis. Infect Immun 2004; 72: 1637-1644.
9. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes underappreciated mediators of innate immune responses. J Immunol 2005; 174: 589-594.
10. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006; 4: 469-476.
11. Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 2004; 72: 6622-6632.
12. Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG, Andersen P. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol 2006; 177: 6353-6360.
13. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis 2005; 85: 47-52.
14. Bonato VL, Lima VM, Tascon RE, Lowrie DB, Silva CL. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998; 66: 169-175.
15. Goncalves ED, Bonato VL, da Fonseca DM, Soares EG, Brandao IT, Soares AP, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 2007; 5: 7.
16. Bafica A, Scanga CA, Serhan C, Machado F, White S, Sher A, et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005; 115: 1601-1606.
17. Machado FS, Aliberti J. Impact of lipoxin-mediated regulation on immune response to infectious disease. Immunol Res 2006; 35: 209-218.
18. Rook GA, Hernandez-Pando R, Zumla A. Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination? J Infect Dis 2009; 199: 613-618.
19. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
20. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8: 369-377.